Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors.
Resource Type
Article
Authors
Borad, Mitesh J. ; Schram, Alison M. ; Kim, Richard D. ; Kamath, Suneel Deepak ; Sahai, Vaibhav ; Dotan, Efrat ; Kelley, Robin Kate ; Ponz-Sarvise, Mariano ; Oh, Do-Youn ; Yachnin, Jeffrey ; Florou, Vaia ; Cassier, Philippe Alexandre ; Park, Joon Oh ; Liao, Chih-Yi ; Millward, Michael ; Ramirez, Florence ; Ricard, Fabien Jean ; Hollebecque, Antoine ; Subbiah, Vivek ; Goyal, Lipika
Source
Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p4009-4009, 1p
Subject
Language
ISSN
0732183X